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BACKGROUND: CD26 is a multifunctional membrane-bound glycoprotein that regulates tumour growth in addition to its other
activities. Because disease aggressiveness is correlated with CD26 expression in several T-cell malignancies, we decided to investigate
the invasiveness of cells expressing different levels of CD26.
METHODS: To assess CD26 involvement in cell invasion, we performed in vitro invasion assays with human T cell lines expressing
different levels of CD26. These included the parental CD26-positive T-lymphoblast cell line HSB-2 and clones infected with a
retrovirus expressing siRNA vectors that either targeted CD26 or encoded a missense siRNA, and the parental CD26-negative
T-leukaemia cell line Jurkat and clones expressing CD26. CD26 expression in these cell lines was evaluated by flow cytometry and
western immunoblotting. CXCR4 expression, phosphorylation of signalling kinases, and MMP-9 secretion were also evaluated by
western immunoblotting, whereas MMP-9 activity and the effect of kinase and CD45 inhibitors on activity were measured by
zymography of conditioned media.
RESULTS: The presence of CD26 enhanced stromal-cell-derived factor-1-a (SDF-1-a)-mediated invasion of T cell lines. This process
was regulated in part by the PI-3K and MEK1 pathways, as indicated by increased phosphorylation of p44/42 MAP kinase and Akt
in the presence of SDF-1-a and the effect of their respective inhibitors on MMP-9 secretion and in vitro invasion. In addition,
CD26-associated enhancement of SDF-1-a-induced invasion was decreased when CD45 was inhibited.
CONCLUSIONS: Our results indicate that the expression of CD26 in T cell lines leads to increased SDF-1-a-mediated invasion in an
in vitro system and that this is controlled in part by the PI-3K and MEK1 pathways. The data also suggest that CD26 enhancement of
invasion may be mediated by CD45, however, more studies are required to confirm this involvement.
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CD26 (DPPIV) is a multifunctional membrane-bound glycoprotein
present on the surface of many cell types. It has three domains: an
extracellular domain which contains its enzyme activity, a trans-
membrane region, and a short cytoplasmic tail of six amino acids,
enabling it to interact with both intra- and extracellular molecules.
CD26 is critical in T-cell biology, as a marker of T-cell activation and
by virtue of its involvement in various signalling pathways (Fox et al,
1984; Dang et al,1 9 9 0 a , b ;T o r i m o t oet al, 1991). Association with
various proteins including fibroblast-activation protein-a (FAPa),
plasminogen, adenosine deaminase, CD45, collagen, and fibronectin,
influences its activity. As a result, CD26 has an important, but
complex, function in tumour behaviour, with its biological effect
dependent on the tumour type and the microenvironment. Likely as
a result of this multifunctional character, CD26 is associated with a
high level of clinical aggressiveness in some tumours but a lower
level in others (Iwata and Morimoto, 1999; Kajiyama et al,2 0 0 2 ;
Havre et al, 2008). For example, it is a marker of aggressive disease
for certain subsets of T-cell non-Hodgkin’s lymphomas/leukaemias,
with expression of CD26 on T-lymphoblastic lymphomas/acute
lymphoblastic leukaemia cells being associated with a worse outcome
compared with CD26-negative tumours (Carbone et al, 1995). CD26 is
also expressed at high levels on malignant mesothelioma (Inamoto
et al, 2007) and renal carcinoma cells (Droz et al, 1990; Stange et al,
2000; Inamoto et al, 2006). Two recent studies also correlate CD26
expression and tumourigenesis. In an immunochemical analysis of
152 patients with gastric gastrointestinal stromal tumours, CD26 was
found to be associated with a poorer overall survival (Yamaguchi
et al, 2008). In addition, CD26 can serve as a prognostic marker in
B-cell chronic lymphocytic leukaemia (Cro et al, 2009).
Stromal-cell-derived factor-1-a (SDF-1-a)/CXCL12 and its
receptor CXCR4 have been shown to be critical in tumourigenesis.
Stromal-cell-derived factor-1-a is constitutively expressed in most
tissues (Shirozu et al, 1995), whereas CXCR4 is expressed in many
cancer cell lines and tissues (Burger et al, 1999; Muller et al, 2001;
Bertolini et al, 2002; Schrader et al, 2002) and is able to mediate the
metastasis of a number of cancers (Zlotnik, 2006).
Previous studies from our group and others showed that CD26 is
able to mediate extracellular matrix binding (Cheng et al, 1998, 2003;
Sato et al, 2005) and tumourigenesis (Sato et al, 2005). To evaluate the
mechanism associated with CD26 involvement in cell invasion, we
used two human T cell lines differing in CD26 expression level. The
first is the parental CD26-positive T-lymphoblast cell line HSB-2 and
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sclones infected with retrovirus expressing siRNA vectors that either
targeted CD26 or encoded a missense siRNA. The second is the
parental CD26-negative T-leukaemia cell line Jurkat and clones
transfected with an empty vector or with a vector encoding CD26.
In vitro invasion assays were performed in the presence or absence of
SDF-1-a. Our results showed that expression of CD26 enhanced SDF-
1-a-mediated invasion of human T cell lines. In addition, treatment
with the protein kinase inhibitors LY294002 and PD98059 signifi-
cantly inhibited MMP-9 secretion and cellular invasion. These data
hence indicate that p44/42 MAP kinase (Erk 1/2) and the downstream
mediator of the PI-3K signalling pathway, Akt, are important
regulators of in vitro SDF-1-a-induced invasion. In addition,
inhibition of CD45 activity reduced both MMP-9 secretion and
cellular invasion, suggesting that CD26 may exert its effect on
invasion through its interaction with CXCR4 and CD45.
MATERIALS AND METHODS
Reagents
Bovine serum albumin (BSA), sodium vanadate, b-glycerophos-
phate, sodium fluoride, polybrene (hexadimethrine bromide),
puromycin, TX-100, and gelatin type A (porcine) were purchased
from Sigma-Aldrich (St Louis, MO, USA). LY294002 and SB203580
were from Promega (Madison, WI, USA) whereas PD98059 and the
PTPase CD45 inhibitor, N-(9,10-dioxo-9,10-dihydro-phenan-
threne-2-yl)-2,2-dimethyl-propionamide, were from Calbiochem
(EMD Biosciences Inc., San Diego, CA, USA).
Cell culture
Jurkat cells were originally obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA) and maintained in RPMI
1640 (Hyclone, Logan, UT, USA). Jurkat cells transfected with CD26
have been described previously (Tanaka et al, 1992). HSB-2 cells
were also obtained from ATCC and maintained in Iscove’s modified
Dulbecco’s medium (ATCC). CD26-depleted clones were generated
using siRNA as described previously (Yamochi et al, 2005). All cell
media contained 10% fetal bovine serum (Hyclone), penicillin
(100uml
 1), and streptomycin (100mgml
 1).
siRNA
CD26 sense and anti-sense oligonucleotides were hybridized and
inserted into the RNAi-Ready pSIREN-RetroQ vector (Clontech,
Mountain View, CA, USA) (Yamochi et al, 2005). The target
sequence was 1768–1786 downstream from the start codon
of CD26 mRNA (50-GATCCGATCATGCATGCAATCAACTTCAA
GAGAGTTGATTGCATGCATGATCTTTTTTGGAAG-30). A mis-
sense siRNA vector was also generated and has been described
(50-GATCCGATCTTGCAAGCAAACAACTTCAAGAGAGTTGTTTG
CTTGCAAGATCTTTTTTGGAAG-30)( Y a m o c h iet al, 2005). GP2-293
cells were transfected with siRNA vectors and VSV-G (Clontech) using
Fugene 6 transfection reagent (Roche Diagnostics, Indianapolis, IN,
USA). The virus supernatants were collected 48h following transfec-
tion and frozen until used. HSB-2 cells were infected with viral super-
natants in the presence of polybrene (4mgml
 1)a n ds e l e c t e dw i t h
2.5mgml
 1 puromycin. Clones were obtained by limiting dilution.
Flow cytometry
Cells were washed once with staining buffer (PBS containing
0.5mM EDTA and 1% BSA) and incubated on ice for 30min
with phycoerythrin-conjugated mouse anti-CD26 or isotypic
mouse IgG (Beckman Coulter, Fullerton, CA, USA). After washing
with staining buffer twice, the cells were re-suspended in PBS.
The surface expression of CD26 was analysed by Reflection
(iCyt Visionary Bioscience, Champaign, IL, USA) using WinList
software (Verity Software House, Topsham, ME, USA).
Invasion assay
T-cell invasion assays were carried out using 24-well plates
containing 12 transwell inserts with 5.0mm pores (Corning Inc.,
Corning, NY, USA) as previously described (Shaw, 2005; Redondo-
Munoz et al, 2006). Wells were coated with ECL Cell Attachment
Matrix (Upstate, Temecula, CA, USA) and allowed to dry before
reconstitution in serum-free media (SFM). When SDF-1-a (R&D
Systems Inc., Minneapolis, MN, USA) was added to the media
below transwells, it was used at 20nM. Cells were washed in SFM,
then resuspended in SFM containing 0.1% BSA. Cells (2.5 10
5)
were added to transwells and also to wells without membranes to
obtain total cell number. After 24h, the transwells were rinsed with
PBS above the membrane, fixed in methanol, stained with 0.2%
cresyl violet, and rinsed in water. Invasion level was determined by
dividing the number of cells that passed through the coated
transwell by the total cell number (determined using a hemocyto-
meter or Coulter counter). When inhibitors were present, cells
were preincubated with the inhibitor for 60min at 371C before
adding cells to transwells. Total cell number for this set was
determined using cells incubated with the inhibitor.
Cell lysates
Cells were lysed using RIPA buffer (20mM Tris-Cl (pH 7.5),
140mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl
sulphate(SDS))containing Halt protease inhibitor cocktail
with 5mM EDTA (Pierce, Rockford, IL, USA) and phosphatase
inhibitors (5mM NaF, 1mM b-glycerophosphate, and 1mM sodium
vanadate). Protein concentration was determined using the
bicinchoninic acid protein assay reagent (Pierce).
Induction of phosphorylation
To detect SDF-1-a-induced phosphorylation, 2 10
6 cells per well
were grown overnight in a six-well plate (previously coated with
1% BSA–PBS) in SFM containing 0.1% BSA. Stromal-cell-derived
factor-1-a was added to cells at a final concentration of 10nM for
0–20min before dilution in cold PBS containing 1mM sodium
vanadate and cells were harvested.
Western blots
Equal amounts of protein were run on 7.5 or 10% polyacrylamide
gels. For detection of CD26, samples were heated at 371C instead of
1001C in Laemmli sample buffer because high temperatures
destroyed the epitope recognised by the antibody. Following
transfer, blots were blocked, then probed with one of the following
antibodies: CD26 (R&D Systems Inc.); CXCR4 (Millipore, Billerica,
MA, USA); Akt and phospho-Akt (Ser473); p44/42 MAPK (Erk 1/
2); and phospho-p44/42 MAPK (Cell Signaling, Beverly, MA, USA);
and MMP-9 (R&D Systems Inc.). Horseradish-peroxidase-
conjugated secondary antibodies and the detection reagent, Super-
Signal West Dura Extended Duration Substrate, were from Pierce.
Blots were scanned using a Kodak Image Station 2000R or 4000R
(New Haven, CT, USA). Alternatively, Li-Cor IRDye-conjugated
secondary antibodies were used and blots were scanned using an
Odyssey imager (Li-Cor Biosciences, Lincoln, NE, USA).
Zymography
Six- or twelve-well plates were coated overnight with 1% BSA–
PBS. Cells (2 10
6) were suspended in SFM containing 0.1% BSA
and incubated for 24h before the addition of SDF-1-a (10nM).
After 24h, cells were pelleted and the conditioned media was
combined with Laemmli sample buffer without reducing agent and
run on a 7.5% SDS-polyacrylamide gel containing 1mgml
 1
gelatin as previously described (Gum et al, 1997). The gel was then
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overnight at 371Ci n2 0m M Tris-Cl (pH 7.4), 136mM NaCl, 10mM
CaCl2. Bands were visualised as clear zones following staining with
Coomassie blue (Leber and Balkwill, 1997). Gels were scanned
using a Kodak Image Station 4000R.
Statistical analysis
Wherever applicable, statistical significant differences were
evaluated by determining the standard error of the mean.
RESULTS
Expression of CD26 on HSB-2 cell lines
There is substantial evidence to support the involvement for CD26-
and DPPIV-related proteins in migration and/or invasion (Ghersi
et al, 2001, 2006; Ikushima et al, 2002; Chen, 2003; Gonzalez-Gronow
et al,2 0 0 5 ;Y uet al, 2006). Although the mechanisms may differ
depending on the cell type, several chemokines we initially evaluated
had no effect on cell invasion, whereas SDF-1-a did, which was
somewhat unexpected based on earlier studies (Shioda et al,1 9 9 8 ;
Christopherson et al, 2002). To determine whether CD26 was
involved in SDF-1-a-mediated cell invasion, we infected parental
HSB-2 cells either with an siRNA that targeted CD26 to create CD26-
depleted clones or with a missense siRNA to serve as a control.
Following selection with puromycin and cloning by limiting dilution,
several CD26-depleted clones were selected for further studies.
HSB-2 cell lines were evaluated for CD26 surface expression by
flow cytometry as described in Materials and methods. HSB-2 cells
and cells infected with missense siRNA, H1-2, expressed CD26
(Figure 1A). In contrast, CD26 expression was undetectable for the
three clones 2E5, 2F8, and 2G9. To confirm CD26 expression, we
ran whole-cell lysates on SDS gels, transferred to nitrocellulose,
and probed with an anti-CD26 antibody. Both HSB-2 and H1-2
expressed CD26, but four CD26-depleted clones had a much lower
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Figure 1 SDF-1-a-mediated invasion is higher in HSB-2 cells than in CD26-depleted clones. (A) Cell-surface expression of CD26 on HSB-2 cell lines. (a)
HSB-2 parental (b) H1-2 (c) 2E5 (d) 2F8 (e) 2G9. Left: cells incubated with PE-labeled isotypic control IgG. Right: cells incubated with PE-labeled anti-CD26
antibody. (B) Expression of CD26 in whole-cell extracts. Equal amounts of protein were run in each lane of a 7.5% gel, transferred to nitrocellulose, and
probed with anti-CD26 antibody. Lanes contained HSB-2 parental cells, H1-2, and four clones depleted of CD26: 2E5, 2F8, 2F10, and 2G9. Note that CD26
runs as a dimer (see Materials and Methods). The multiple bands are due to differences in glycosylation. (C) Invasion assay (details in Materials and Methods).
Assays were carried out for 24h, at which time the cells were counted in all wells. Percentage invasion is the number of cells which passed through the
transwell divided by the total cell number. Error bars are shown for the standard error of the mean.
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slevel of CD26 than either the parental HSB-2 or H1-2 cells
(Figure 1B). Note that because extracts were heated at 371C instead
of 1001C before loading, the detected size of CD26 was approxi-
mately 220kDa instead of 110kDa (Ghersi et al, 2002).
SDF-1-a-mediated invasion is higher in HSB-2 cells than in
CD26-depleted clones
To evaluate the function of CD26 in invasion, SDF-1-a, was added
underneath the transwells to obtain a final concentration of 20nM,
as described in Materials and Methods. Following incubation for
24h, cells were counted for each well. No cells remained attached
to the transwell support as confirmed by cresyl violet staining
(data not shown). The presence of SDF-1-a resulted in increased
invasion for both the HSB-2 parent cell line and H1-2 expressing
missense siRNA. However, invasion was not increased for 2E5, was
marginally increased for 2F8, and moderately increased for 2G9
(Figure 1C). Of note is that the difference in invasive activity of the
three CD26-depleted clones was statistically significant when
compared to the CD26-expressing cells. Results are expressed as
percent increased invasion because of variation in the absolute
values for experiments run on different days.
Expression of CD26 on Jurkat cell lines
Another cell type was used to further evaluate CD26 involvement
in SDF-1-a-mediated invasion. Surface expression of CD26 was
determined as previously described for HSB-2 cells. CD26 was not
detected on the surface of parental Jurkat cells or Jurkat cells
transfected with the empty vector Neo (Figure 2A). In contrast,
CD26 was highly expressed on the cell surface of the Jurkat
transfectant wt1. Western blotting with anti-CD26 antibody
confirmed the results from flow cytometry (Figure 2B). There
was no CD26 protein detected in either the parental Jurkat cell line
or Jurkat cells transfected with the empty vector Neo. However,
Jurkat cells transfected with wild-type CD26 expressed a high level
(wt1) of CD26.
SDF-1-a-mediated invasion is elevated in Jurkat
transfectants expressing CD26
Others have shown that CD26-negative Jurkat cells are able to
migrate in response to SDF-1-a (Chernock et al, 2001; Tan et al,
2006), and that migration was dependant on CXCR4 (Tan et al,
2006). Here, in a comparison of parental Jurkat cells, cells
containing the empty vector, and transfectants expressing high
levels of CD26, the CD26-expressing cells exhibited much higher
invasive activity in response to SDF-1-a as compared to the other
cells (Figure 2C). The addition of SDF-1-a did not lead to increased
invasive activity for the parental Jurkat cells or for Jurkat cells
transfected with the empty vector.
CXCR4 level is not dependant on CD26 expression and is
not affected by SDF-1-a
Stromal-cell-derived factor-1-a presence has been shown to up-
regulate CXCR4 expression in the prostate cancer cell line PC-3
(Kukreja et al, 2005). We therefore considered the possibility that
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Figure 2 SDF-1-a-mediated invasion is elevated in Jurkat transfectants expressing CD26. (A) Cell-surface expression of CD26 on Jurkat cell lines. (a)J u r k a t -
parental, CD26-negative (b)J u r k a t - N e o( c) Jurkat-Wt1. Left: cells incubated with PE-labeled isotypic control IgG. Right: cells incubated with PE-labeled anti-CD26
antibody. (B) Expression of CD26 in whole-cell extracts. Equal amounts of protein were run in each lane of a 7.5% gel, transferred to nitrocellulose, and probed
with anti-CD26 antibody. Lanes contained Jurkat-parental, Neo cells transfected with empty vector, and wt1 transfectant expressing high levels of CD26,
respectively. Note that CD26 runs as a dimer. (C) Invasion assay (as described for Figure 1C). Error bars are shown for the standard error of the mean.
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sthere might be a difference in the expression of CXCR4 among the
parental cells and clones differing in CD26 levels. Furthermore, the
possibility that CD26-expressing cells might upregulate CXCR4 in
response to SDF-1-a, whereas CD26-negative cells might be
resistant to change was also evaluated. Cells were maintained
overnight in SFM containing 0.1% BSA, and SDF-1-a was added
the following day at a final concentration of 10nM. Whole-cell
lysates were prepared and run on gels, transferred to nitrocellu-
lose, and probed with anti-CXCR4 antibody. Our data showed that
CXCR4 level was not affected by SDF-1-a (Figure 3). In addition,
CXCR4 expression did not vary significantly among parental cells
expressing CD26 (HSB-2 and H1-2) and CD26-depleted clones
(2E5, 2F8, and 2G9) or among CD26-negative parental Jurkat cells
(Jurkat and Neo) and a CD26-overexpressing clone (wt1).
SDF-1-a induces phosphorylation of signalling proteins in
T cell lines
Phosphorylation of several signalling proteins has been shown to
be important in in vitro cell migration or invasion for various cell
types. For example, Akt activation is required for migration of
HeLa cells (Peng et al, 2005), whereas activation of PI-3K and
p44/42 MAPK is required for SDF-1-a-dependent T-cell migration
(Sotsios et al, 1999). In prostate cancer cells, PI-3 kinase and p44/
p42 MAPK were shown to be important for SDF-1-a-mediated
invasion (Chinni et al, 2006), whereas in breast cancer cells PI-3K,
but not p44/p42 MAPK, was required (Fernandis et al, 2004). To
determine the signalling pathways involved in CD26-regulated
invasive activity of T cell lines, we evaluated the phosphorylation
status of the key intracellular signalling molecules p44/42 MAPK
and Akt following incubation of cells with SDF-1-a at various time
points, as described in Materials and methods. For HSB-2 cells,
there was a minimal level of p44/42 MAPK (Erk 1/2) phosphoryla-
tion in the absence of SDF-1-a (Figure 4A). Following the addition
of SDF-1-a, phosphorylation level increased between 1 and 10min
of incubation, but decreased substantially after 20min of incuba-
tion. Phosphorylation of Akt was also low in the absence of SDF-1-
a, but increased by 2.5min on incubation with the chemokine.
Stromal-cell-derived factor-1-a-mediated phosphorylation of key
signalling molecules was similarly evaluated for the CD26-
expressing Jurkat clone wt1 (Figure 4B). Phosphorylation of p44/
42 MAPK was induced following incubation with SDF-1-a, peaking
by 5min and returning to baseline level by 20min. In addition,
phosphorylation of Akt was induced by SDF-1-a, gradually
increasing in intensity between 0 and 20min of incubation.
Kinase inhibitors decrease invasion in T cell lines
To confirm the function of key signalling pathways in SDF-1-a-
mediated invasion of CD26-expressing T cell lines, we incubated
CXCR4
SDF-1- + − − − − − + + ++
− − − + + +
HSB-2 H1-2 2E5 2F8 2G9
Jurkat Neo wt1
SDF-1-
CXCR4
Figure 3 CXCR4 level is not dependant on CD26 expression and is not
affected by SDF-1-a. Expression of CXCR4 in whole-cell lysates. Equal
amounts of protein were run in each lane of a 7.5% gel, transferred to
nitrocellulose, and probed with anti-CXCR4 antibody. (A) Lanes contained
HSB-2 parental cells, H1-2 (parental cells with control siRNA), and three
CD26-depleted clones: 2E5, 2F8, and 2G9. (B) Lanes contained CD26-
negative Jurkat parental cells, Neo (parental cells with empty vector), and
wt1, a CD26-overexpressing clone. When SDF-1-a was present (þ), it
was at a final concentration of 10nM.
N
o
 
S
D
F
1
 
m
i
n
2
.
5
 
m
i
n
5
.
0
 
m
i
n
1
0
 
m
i
n
2
0
 
m
i
n
10 nM SDF-1-
Phospho-p44 MAPK
Phospho-p42 MAPK
p44 MAPK
p42 MAPK
Phospho-Akt (Ser473)
N
o
 
S
D
F
2
.
5
 
m
i
n
5
.
0
 
m
i
n
1
0
.
0
 
m
i
n
10 nM SDF-1-
pAkt
Phospho-p44 MAPK
N
o
 
S
D
F
1
 
m
i
n
2
.
5
 
m
i
n
5
.
0
 
m
i
n
1
0
 
m
i
n
2
0
 
m
i
n
10 nM SDF-1-
p44 MAPK
Phospho-p42 MAPK
p42 MAPK
N
o
 
S
D
F
1
 
m
i
n
2
.
5
 
m
i
n
5
.
0
 
m
i
n
1
0
 
m
i
n
2
0
 
m
i
n
10 nM SDF-1-
Phospho-Akt (Ser473)
pAkt
Figure 4 SDF-1-a induces phosphorylation of signalling proteins in T cell lines. (A) Activation of signalling kinases in HSB-2 cells following incubation with
SDF-1-a. Cells were incubated with 10nM SDF-1-a for the indicated times, run on gels, transferred to nitrocellulose, then probed with site-specific
antibodies. Top left, phosphorylated MAPK p44/42 (thr202/tyr204); bottom left, phosphorylated Akt (Ser473). Data depicted are representative of two
separate experiments. (B) Activation of signalling kinases in Jurkat wt1. Top right, phosphorylated MAPK p44/42 (thr202/tyr204); bottom right,
phosphorylated Akt (Ser473). Data depicted are representative of three separate experiments. Total p44/42 MAPK and Akt are shown below their
respective phosphorylated kinases.
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in vitro invasion assays (Table 1). Inhibition of PI-3K by LY294002
and MEK1 by PD98059 resulted in a significant decrease in
invasive activity for both cell types. In contrast, the p38 MAPK
inhibitor, SB203580, had a marginal effect on invasion. Because
Akt is a downstream effector of PI-3K, these results indicate that
activation of both Akt and p44/42 MAPK, but not p38 MAPK, is
required for SDF-1-a-dependent invasion of CD26-expressing T
cell lines.
MMP-9 is induced in HSB-2 cells but not in CD26-depleted
clones
Because previous studies have reported a link between MMP-9
production and invasion (Kim et al, 2001; Redondo-Munoz et al,
2006), we examined potential MMP-9 induction following a 24h
treatment with SDF-1-a. Conditioned media was analysed by
zymography and by western blots. For zymography, clear zones
represent digested gelatin present in the gel. MMP-9 was induced
in the CD26-expressing parental HSB-2 cells and H1-2 when SDF-
1-a was present. In contrast, MMP-9 was not induced in the CD26-
depleted clone 2E5, but moderately induced in clones 2F8 and 2G9
as shown by the clear zones (Figure 5A). This pattern parallels the
one obtained for invasion where 2E5 showed no increase in
invasion in the presence of SDF-1-a, whereas the other two clones,
2F8 and 2G9, showed a moderate increase in invasion (Figure 1A).
Western blotting of the conditioned media further confirmed that
MMP-9 secretion increased in HSB-2 and H1-2 cells, but did not
increase for 2E5 and moderately increased for 2F8 and 2G9
(Figure 5B).
Because Akt has been shown previously to regulate MMP-9
induction (Kim et al, 2001), we next examined the potential function
of Akt in our system by pre-incubating HSB-2 or H1-2 cells with the
PI-3K inhibitor LY294002 for 30min before the addition of SDF-1-a.
MMP-9 secretion was decreased in the presence of the inhibitor,
indicating that Akt is involved in SDF-1-a-mediated secretion of
MMP-9 in CD26-expressing cells (Figure 5C). In addition, inhibition
of p44/42 MAPK activation using the MEK1 inhibitor PD98059 and
CD45 activity using N-(9,10-dioxo-9,10-dihydro-phenanthrene-2-yl)-
2,2-dimethyl-propionamide also reduced MMP-9 secretion in both
HSB-2 and H1-2 cells (Figure 5C).
Invasion is inhibited in the presence of a CD45 inhibitor
Because several studies have shown previously that CD45
expression enhances migration (Harvath et al, 1991; Fernandis
et al, 2003; Okabe et al, 2006), and because our group has
demonstrated that CD26 association with CD45 results in
enhanced phosphorylation of several signalling kinases, including
p44/42 MAPK (Torimoto et al, 1991; Hegen et al, 1997; Ishii et al,
2001), we were interested in the effect of CD45 inhibition on
SDF-1-a-mediated invasion in CD26 expressing cells. T cells
were incubated with a CD45 inhibitor for 1h before performing
the invasion assays. CD45 inhibitor decreased invasive activity
for both CD26-expressing parental HSB-2 cells and Jurkat wt1
transfectants (Figure 6). The level of invasive activity in the
presence or absence of SDF-1-a was consistent with data obtained
from previous assays (Figures 1C and 2C). Pre-treatment with the
CD45 inhibitor, however, resulted in decreased invasive activity for
both cell lines. These results suggest that CD26 may be exerting its
effect on SDF-1-a-mediated invasion through its association with
CXCR4 and CD45.
DISCUSSION
Because disease aggressiveness is correlated with CD26 expression
in several T-cell malignancies (Havre et al, 2008), we decided to
investigate in vitro invasiveness of T cells expressing different
levels of CD26. Chemotaxis and invasion of tumour cells are
critical for the development of metastasis, which is governed in
Table 1 Invasion is inhibited in the presence of kinase inhibitors
Inhibitor Inhibition for wt1 (%) Inhibition for H1-2 (%)
LY294002 70.4 48.5
PD98059 50.0 35.4
SB203580 12.8 23.8
Cells were incubated with inhibitors for 1h before the start of invasion assays. The
phosphatidylinositol 3-kinase (PI-3K) inhibitor, LY294002, and the MEK1 inhibitor,
PD98059, were used at a concentration of 50mM, whereas the p38 MAP kinase
inhibitor, SB203580, was used at a concentration of 10mM. Invasion level was
determined following 24h of incubation in the presence of SDF-1-a. Per cent
inhibition¼per cent invasion in the absence of inhibitor per cent invasion in the
presence of inhibitor/per cent invasion in the absence of inhibitor. Data depicted are
representative of two separate experiments.
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Figure 5 MMP-9 is induced in HSB-2 cells but not in CD26-depleted
clones. Cells were incubated with or without SDF-1-a (see Materials and
methods). Cells were harvested at 24h and the conditioned media was run
on gels. (A) Equal volumes of conditioned media were loaded on an
acrylamide gel containing 0.1% gelatin. Following staining, clear zones
corresponding to digested gelatin could be detected. (B) Conditioned
media was run on a 7.5% acrylamide gel and then probed with anti-MMP-9
antibody following transfer to nitrocellulose. (C) Inhibitors were added
30min before the addition of SDF-1-a to both HSB-2 and H1-2 cells. The
PI-3K inhibitor, LY294002, was added at a concentration of 12mM, the
MEK1 inhibitor, PD98059, was at 11mM, and the CD45 inhibitor, N-(9,10-
dioxo-9,10-dihydro-phenanthrene-2-yl)-2,2-dimethyl-propionamide, was at
1.5mM. No SDF (clear bars), SDF and vehicle (solid bars), SDF and MEK1
inhibitor (dots, low density), SDF and CD45 inhibitor (dots, high density),
SDF and PI-3K inhibitor (bricks). Gels were scanned and the clear zones
quantified after inverting the image. Data depicted are representative of
three experiments.
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and matching chemokines on target organs. Although it is well
established that SDF-1-a increases migration of cells expressing
CXCR4 (Ganju et al, 1998; Sotsios et al, 1999), only a few studies
have demonstrated the effect of SDF-1-a on invasion (Fernandis
et al, 2004; Chinni et al, 2006). In prostate cancer cells, PI-3 kinase
and p44/p42 MAPK were shown to be important for SDF-1-a-
mediated invasion (Chinni et al, 2006), whereas in breast cancer
cells PI-3K, but not p44/p42 MAPK, was required (Fernandis et al,
2004).
In addition to protein kinases, several tyrosine phosphatases
have been shown to be important for migration. The expression
of SHP-1 appears to be inversely correlated with migration
in haematopoetic cells from mice (Kim et al, 1999), whereas
SHP2 overexpression increases SDF-1-a-induced chemotaxis in
human lymphocytes (Chernock et al, 2001). Another tyrosine
phosphatase, CD45, has also been shown to enhance cell migra-
tion in response to SDF-1-a (Harvath et al, 1991; Fernandis et al,
2003; Okabe et al, 2006). However, the effect of CD45 on invasion
has not previously been reported. In our studies, invasion was
decreased in the presence of a CD45 inhibitor. Association of CD26
with CD45 has been reported to result in increased signal
transduction, including increased p44/42 MAPK activity (Torimoto
et al, 1991; Hegen et al,1 9 9 7 ;I s h i iet al, 2001). Moreover, both
CD26 and CD45 associate with CXCR4 in lymphocytes (Herrera
et al, 2001; Fernandis et al, 2003). The consequences of the
association of CXCR4 and CD26 are not understood. Binding
of SDF-1-a triggers internalization of both CXCR4 and CD26 in the
T cell line Jurkat, the B-cell line SKW6.4, and peripheral blood
lymphocytes (Herrera et al,2 0 0 1 ) ,b u tt h ei m p o r t a n c eo fi n t e r n a l i z -
ation for signalling enhancement is controversial (Neel et al,
2005).
CD26 also interacts with several other proteins that could
promote its role in invasion. It binds to plasminogen 2e in the
prostate cancer cell line 1-LN, triggering an intracellular [Ca
2þ]
flux leading to the upregulation of MMP-9 (Gonzalez-Gronow et al,
2001). CD26 has also been shown to form heterodimers with FAPa,
colocalizing at pseudopodia and causing secretion/activation of
MMPs in migratory fibroblasts and endothelial cells (Ghersi et al,
2002, 2006).
It is well documented that CD26 can cleave and inactivate SDF-
1-a. It has been shown that SDF-1-a is cleaved by soluble CD26
in vitro (Ohtsuki et al, 1998; Proost et al, 1998; Lambeir et al,
2001), resulting in the inactivation of its chemotactic activity. In
addition, there are several reports of reduced migration in the
presence of SDF-1-a when cells express CD26 (Shioda et al, 1998;
Christopherson et al, 2002). However, substrate recognition and
cleavage efficiency is likely to be dependant on CD26-associated
proteins and the local concentration of SDF-1-a. Studies using
purified CD26 showed Km values ranging from 5 to 60mM for
natural Xaa-pro and Xaa-ala peptides with 7–42 residues.
However, in vivo regulatory peptides act in the pico- and
nanomolar range, so micromolar concentrations are not reached
(Mentlein, 1999). Therefore, a number of factors including the
microenvironment are likely to determine whether CD26 enhances
or diminishes invasion.
There is a growing list of malignancies in which CD26 is
involved. It is a marker of aggressive disease for selected subsets of
T-cell non-Hodgkin’s lymphomas/leukaemias (Carbone et al,
1995). It is also expressed at high levels on malignant mesothe-
lioma (Inamoto et al, 2007) and renal carcinoma cells (Droz et al,
1990; Stange et al, 2000; Inamoto et al, 2006) and was found to be
associated with poorer overall survival in patients with gastric
gastrointestinal stromal tumours (Yamaguchi et al, 2008). Our
present work shows that SDF-1-a-mediated invasion was enhanced
in CD26-expressing T cell lines. Invasion was partially regulated by
the PI-3K and MEK1 pathways as shown by increased phosphor-
ylation of p44/42 MAPK and Akt in the presence of SDF-1-a and by
decreased MMP-9 secretion and in vitro invasion in the presence
of their respective inhibitors. Our data also suggest that CD26
enhancement of invasion may be mediated by CD45.
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